資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31014
|
| 標題: | Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor |
| 作者: | Tu, Dom-Gene
Yu, Yun
Lee, Che-Hsin
Kuo, Yu-Liang
Lu, Yin-Che
Tu, Chi-Wen
Chang, Wen-Wei |
| 貢獻者: | Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Nucl Med
Chia Nan Univ Pharm & Sci, Dept Food Sci & Technol
Chang Jung Christian Univ, Coll Hlth Sci, Grad Inst Med Sci
Chung Shan Med Univ, Coll Med Sci & Technol, Sch Biomed Sci
China Med Univ, Sch Med, Grad Inst Basic Med Sci
China Med Univ, Sch Med, Dept Microbiol
Chung Shan Med Univ Hosp, Dept Med Imaging
Chung Shan Med Univ, Sch Med Imaging & Radiol Sci
Chia Yi Christian Hosp, Ditmanson Med Fdn, Div Hematol Oncol
Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Surg
Chung Shan Med Univ Hosp, Dept Med Res |
| 關鍵字: | hinokitiol
vasculogenic mimicry
breast cancer stem
progenitor cells
epidermal growth factor receptor
differentiation |
| 日期: | 2016-04 |
| 上傳時間: | 2018-01-18 11:39:51 (UTC+8) |
| 出版者: | Spandidos Publ Ltd |
| 摘要: | Hinokitiol, alternatively known as -thujaplicin, is a tropolone-associated natural compound with antimicrobial, anti-inflammatory and antitumor activity. Breast cancer stem/progenitor cells (BCSCs) are a subpopulation of breast cancer cells associated with tumor initiation, chemoresistance and metastatic behavior, and may be enriched by mammosphere cultivation. Previous studies have demonstrated that BCSCs exhibit vasculogenic mimicry (VM) activity via the epidermal growth factor receptor (EGFR) signaling pathway. The present study investigated the anti-VM activity of hinokitiol in BCSCs. At a concentration below the half maximal inhibitory concentration, hinokitiol inhibited VM formation of mammosphere cells derived from two human breast cancer cell lines. Hinokitiol was additionally indicated to downregulate EGFR protein expression in mammosphere-forming BCSCs without affecting the expression of messenger RNA. The protein stability of EGFR in BCSCs was also decreased by hinokitiol. The EGFR protein expression and VM formation capability of hinokitiol-treated BCSCs were restored by co-treatment with MG132, a proteasome inhibitor. In conclusion, the present study indicated that hinokitiol may inhibit the VM activity of BCSCs through stimulating proteasome-mediated EGFR degradation. Hinokitiol may act as an anti-VM agent, and may be useful for the development of novel breast cancer therapeutic agents. |
| 關聯: | Oncology Letters, v.11 n.4, pp.2934-2940 |
| 顯示於類別: | [ 食品科技系 ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 31014.pdf | | 672Kb | Adobe PDF | 355 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1290 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
